The Zacks Analyst Blog Meta, Pfizer, Salesforce and Smith-Midland
- ๐ฐ Zacks Equity Research analysts featured four specific stocksโMeta, Pfizer, Salesforce, and Smith-Midlandโin their daily Analyst Blog dated May 14, 2026.
- ๐ Meta Platforms shares have declined -7.9% over the past year, underperforming its industry average of -16.2%.
- ๐ป Meta is increasing infrastructure spending to build frontier models and data centers despite cost inflation in AI.
- ๐ง Reality Labs continues to operate at a loss while the payoff from Meta AI agents remains in early development stages.
- โ๏ธ Elevated regulatory and litigation scrutiny persists as significant headwinds for Meta Platforms, Inc.
- ๐ Pfizer Inc. shares have gained +25.9% year-over-year, slightly trailing its industry peer group of +29.9%.
- ๐ Pfizer beat first-quarter earnings and sales estimates following a multi-year decline driven by reduced COVID-related product sales.
- ๐ Non-COVID revenue at Pfizer is improving due to key products like Vyndaqel, Padcev, and Eliquis, along with new launches.
- โ ๏ธ The pharmaceutical company faces upcoming patent expirations for key drugs scheduled between 2026 and 2030.
- ๐ Pfizer's 2026 revenue and earnings guidance indicates mostly flat to slightly negative growth prospects overall.
- ๐๏ธ Salesforce Inc. shares have underperformed the Internet-Software industry significantly, dropping -41.7% compared to a -16.2% industry decline.
- ๐ธ Salesforce faces challenges from stiff competition, unfavorable currency fluctuations, and a challenging macroeconomic environment.
- ๐ Demand remains robust for Salesforce as customers undergo major digital transformations aligned with the company's top-line growth.
- ๐ค Strategic acquisitions such as Slack, Informatica, and Waii have broadened Salesforceโs portfolio and improved competitiveness.
- ๐๏ธ Smith-Midland Corp. shares have underperformed its Building Products industry, falling -2.7% versus a +14.3% gain for the sector.
- ๐๏ธ This micro-cap company focuses on shifting toward higher-margin, recurring, and asset-light revenue streams supported by infrastructure demand.
- ๐ Smith-Midlandโs nine-month rental revenues surged 88% year-over-year driven by high utilization of MASH-compliant fleets.
- ๐งฑ Proprietary SlenderWall contributed $1.1 million in Q3 after no prior-year sales, while soundwalls grew 52% year-over-year.
- ๐ฐ The company maintains a strong balance sheet with a $54.8-million backlog supporting visibility into 2026 growth.
- ๐ Royalty income for Smith-Midland increased 13% year-over-year, providing scalable and high-margin IP monetization.
- โ๏ธ Smith-Midland maintained resilient margins at 26.8% through disciplined cost control despite market shifts.
- ๐ Zacks Equity Research offers daily research reports and "Ahead of Wall Street" articles available for free on their homepage.
- ๐ค Sheraz Mian heads the Zacks Equity Research department and is noted as a well-regarded expert in aggregate earnings.
- Meta Platforms is extending AI deeper across Facebook, Instagram, WhatsApp and Threads, with engagement and ad efficiency lifting due to recommendation upgrades and advertiser tools.
- Management is building frontier models, agents, and data center capacity while securing supply chains, which will keep the core ads engine advancing and expand monetization in messaging, commerce, and creator tools.
- Pfizer beat first-quarter estimates for earnings and sales, marking a recovery phase as its non-COVID operational revenues improve from key products like Vyndaqel, Padcev, and Eliquis.
- Salesforce is benefiting from a robust demand environment where customers are undergoing a major digital transformation, sustaining focus on aligning products with customer needs to drive the top line.
- Continued deal wins in the international market for Salesforce serve as another growth driver, supported by partnerships with Amazon and Alphabet to expand global operations.
- Smith-Midland's nine-month rental revenues surged 88% year over year due to high utilization and margin-accretive MASH-compliant fleets, serving as a core growth driver.
- New product lines for Smith-Midland contributed significant revenue in Q3: Proprietary SlenderWall contributed $1.1 million, soundwalls grew 52% year over year, and Easi-Set modular buildings rose 50% year over year.
- Smith-Midland maintains resilient margins at 26.8% with disciplined cost control and a strong balance sheet that supports continued investment.
- Shares of Meta have declined -7.9% over the past year, though underperformance relative to its industry (-16.2%) suggests it has lagged peers during a broader downturn.
- Meta's cost inflation in AI infrastructure is pushing spending higher, while Reality Labs remains loss-generating.
- The payoff from Meta AI and agents is still developing, creating uncertainty about near-term revenue contributions from these key initiatives.
- Regulatory and litigation scrutiny remains elevated overall for the company, posing potential financial and reputational risks.
- Management is leaning into a multi-year buildout of frontier models and data center capacity, which could strain cash flows without guaranteed returns.
- Shares of Pfizer face challenges from upcoming patent expirations of some key drugs in the 2026-2030 period, which could impact future revenue streams.
- Pfizer's revenues and earnings guidance for 2026 indicates mostly flat to slightly negative growth, signaling near-term stagnation or decline.
- The company has taken a hit over the past three years due to a sharp decline in sales of its COVID-related products, leaving it vulnerable to post-pandemic headwinds.
- Salesforce is underperforming its industry significantly (-41.7% vs -16.2%), raising concerns about competitive positioning despite market-wide weakness.
- Unfavorable currency fluctuations are impacting Salesforce's financial performance in international markets.
- A challenging macroeconomic environment could hurt Salesforce's growth prospects and customer spending on enterprise software.
- Smith-Midland's shares have underperformed its industry (-2.7% vs +14.3%), indicating specific operational or market weaknesses despite niche growth drivers.